Sunitinib and pazopanib are two effective medications from tyrosine kinase inhibitor pharmacologic class for the first-line treatment of metastatic renal cell carcinoma (mRCC). Nevertheless, the adverse side effects during treatment often lead to dose reductions or even treatment discontinuations. In order to provide the most efficient treatment to mRCC patients, efficacy and safety of these […]
Read More